CAR T cell therapy biotech Poseida Therapeutics files for a $115 million IPO

Shutterstock photo

Poseida Therapeutics, a Phase 1 biotech developing CAR T cell therapies for multiple myeloma and prostate cancer, filed on Friday with the SEC to raise up to $115 million in an initial public offering.

The San Diego, CA-based company was founded in 2014 and plans to list on the Nasdaq under the symbol PSTX. Poseida Therapeutics filed confidentially on November 1, 2018. Citi, Credit Suisse and Wells Fargo Securities are the joint bookrunners on the deal. No pricing terms were disclosed.

The article CAR T cell therapy biotech Poseida Therapeutics files for a $115 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital


Research Brokers before you trade

Want to trade FX?